11/18
12:36 pm
cybn
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Medium
Report
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
11/18
07:12 am
cybn
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]
High
Report
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]
11/18
07:00 am
cybn
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
High
Report
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
11/14
11:13 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $96.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $96.00 to $86.00. They now have a "buy" rating on the stock.
11/14
07:30 am
cybn
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Low
Report
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
11/13
07:30 am
cybn
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
High
Report
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
10/31
07:30 am
cybn
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
Low
Report
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
10/24
07:30 am
cybn
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
Low
Report
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
10/24
07:13 am
cybn
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program [Yahoo! Finance]
Low
Report
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program [Yahoo! Finance]
10/15
12:31 pm
cybn
Cybin: Top Value Psychedelic Stock [Seeking Alpha]
Low
Report
Cybin: Top Value Psychedelic Stock [Seeking Alpha]
10/3
07:30 am
cybn
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
Low
Report
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
10/1
07:30 am
cybn
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
Medium
Report
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
9/27
11:57 am
cybn
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” [Yahoo! Finance]
Low
Report
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” [Yahoo! Finance]
9/24
07:30 am
cybn
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Low
Report
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
9/23
11:16 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $114.00 to $96.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $114.00 to $96.00. They now have a "buy" rating on the stock.
9/19
05:43 pm
cybn
Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]
Medium
Report
Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]
9/19
05:38 pm
cybn
Cybin Provides Corporate Update on Upcoming Clinical Milestones
High
Report
Cybin Provides Corporate Update on Upcoming Clinical Milestones
9/19
08:21 am
cybn
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale [Seeking Alpha]
High
Report
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale [Seeking Alpha]
9/19
07:31 am
cybn
Cybin Announces Completion of Previously Announced Share Consolidation [Yahoo! Finance]
High
Report
Cybin Announces Completion of Previously Announced Share Consolidation [Yahoo! Finance]
9/19
07:26 am
cybn
Cybin Announces Completion of Previously Announced Share Consolidation
High
Report
Cybin Announces Completion of Previously Announced Share Consolidation
9/4
08:34 am
cybn
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]
Low
Report
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]
9/4
07:55 am
cybn
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
8/27
07:07 pm
cybn
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation [Yahoo! Finance]
Low
Report
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation [Yahoo! Finance]
8/27
07:01 pm
cybn
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
Low
Report
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
8/23
08:09 am
cybn
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.